63
Table 2 (continued)
Compound
Pharmaceutical
activity
Optimal deep eutectic
solvent composition(s)
Therapeutic
deep
eutectic
solvents
References
Ginkgolide B
Plateletactivating factor
antagonist
PD:CC:W 1:1:1
Dai et al.
(2013)
Ginkgolide B
Plateletactivating factor
antagonist
CC:G
Choi et al.
(2011)
Griseofulvin
Antifungal
CC:MOA 1:1
Morrison et al.
(2009)
Ibuprofen
Antiinflammatory
TPAB:PD 1:2
Lu et al. (2016)
Ibuprofen
Antiinflammatory
Drug:menthol
✓
Aroso et al.
(2015) and
Duarte et al.
(2017)
Ibuprofen
Antiinflammatory
Drug:various HBA
✓
Wolbert et al.
(2019)
Ibuprofen
Antiinflammatory
CC:drug
✓
Abranches
et al. (2019)
Imipenem
Antibiotic
B:U 1:1.5
Olivares et al.
(2018)
Indomethacin
Antiinflammatory
TBAB:EG; TBAB:GL
Mokhtarpour
et al. (2019b)
Itraconazole
Antiinflammatory
CC:GA 1:2; CC:GA:OA
1:1.7:0.3
Li and Lee
(2016)
Itraconazole
Antifungal
CC:MOA 1:1
Morrison et al.
(2009)
Ketoprofen
Antiinflammatory
TPAB:PD 1:2
Lu et al. (2016)
Ketoprofen
Antiinflammatory
CC:drug
✓
Abranches
et al. (2019)
Lamotrigine
Antiepileptic
CC:EG
Shekaari et al.
(2019)
L-arginine
Amino acid
CA:L-Arg:W various
ratios
✓
Santos et al.
(2019)
Lidocaine
Local anesthetic CC:GA 1:2; CC:GA:OA
1:1.7:0.3
Li and Lee,
(2016)
Lidocaine
Local anesthetic CC:LA; β-ala:LA;
Arg:GLA; Arg:OA;
Arg:TA
Gutiérrez et al.
(2018, 2019)
Lidocaine
Local anesthetic Various HBA, including
thymol
✓
Wolbert et al.
(2019)
Lidocaine
Local anesthetic Prilocaine
✓
Wojnarowska
et al. (2018)
(continued)
2 Deep Eutectic Solvents for Innovative Pharmaceutical Formulations